Single User License
INR 102030
Site License
INR 204060
Corporate User License
INR 306090

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


F. Hoffmann-La Roche Ltd.-Product Pipeline Review-2015

F. Hoffmann-La Roche Ltd.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

F. Hoffmann-La Roche Ltd.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'F. Hoffmann-La Roche Ltd.-Product Pipeline Review-2015', provides an overview of the F. Hoffmann-La Roche Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of F. Hoffmann-La Roche Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of F. Hoffmann-La Roche Ltd. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of F. Hoffmann-La Roche Ltd.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the F. Hoffmann-La Roche Ltd.'s pipeline products

Reasons To Buy

Evaluate F. Hoffmann-La Roche Ltd.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of F. Hoffmann-La Roche Ltd. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the F. Hoffmann-La Roche Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of F. Hoffmann-La Roche Ltd. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of F. Hoffmann-La Roche Ltd.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of F. Hoffmann-La Roche Ltd. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

F. Hoffmann-La Roche Ltd. Snapshot 7

F. Hoffmann-La Roche Ltd. Overview 7

Key Information 7

Key Facts 7

F. Hoffmann-La Roche Ltd.-Research and Development Overview 8

Key Therapeutic Areas 8

F. Hoffmann-La Roche Ltd.-Pipeline Review 17

Pipeline Products by Stage of Development 17

Pipeline Products-Monotherapy 18

Pipeline Products-Combination Treatment Modalities 19

Pipeline Products-Partnered Products 20

Pipeline Products-Out-Licensed Products 23

F. Hoffmann-La Roche Ltd.-Pipeline Products Glance 25

F. Hoffmann-La Roche Ltd.-Late Stage Pipeline Products 25

F. Hoffmann-La Roche Ltd.-Clinical Stage Pipeline Products 28

F. Hoffmann-La Roche Ltd.-Early Stage Pipeline Products 32

F. Hoffmann-La Roche Ltd.-Drug Profiles 36

bevacizumab 36

cobimetinib 41

ibandronate sodium 45

omalizumab 47

pertuzumab 49

alectinib 52

alteplase 53

atezolizumab 54

gantenerumab 56

lebrikizumab 58

obinutuzumab 60

ocrelizumab 62

ranibizumab 64

tocilizumab 67

trastuzumab emtansine 70

vemurafenib 74

(danoprevir + ritonavir) 77

basimglurant 78

bitopertin 80

codrituzumab 82

danoprevir 84

emactuzumab 87

imgatuzumab 88

miravirsen 90

pirfenidone 92

RG-1577 95

RG-1662 97

RG-6013 98

RG-7314 99

RG-7697 100

RG-7929 101

RO-5093151 102

setrobuvir 104

TRX-1 106

vanucizumab 107

vismodegib 108

lumretuzumab 111

RG-6016 113

RG-7388 115

RG-7800 116

PRX-002 118

RG-6080 119

RG-7203 120

RG-7304 121

RG-7342 122

RG-7345 123

RG-7356 124

RG-7410 125

RG-7625 126

RG-7641 127

RG-7689 128

RG-7716 129

RG-7775 130

RG-7787 131

RG-7795 132

RG-7802 134

RG-7813 135

RG-7876 136

RG-7880 137

RO-5285119 138

RO-6799477 139

RO-6806127 140

RO-6836191 141

RO-6864018 142

RO-6870868 143

RO-6889678 144

RO-6926496 145

RO-7033877 146

SPC-2968 147

Antisense Oligonucleotide to Target miR-33 for Cardiovascular Diseases 149

AT-006 150

Benzodiazepinone-36 151

Benzoxazepinone-40 152

CLP-257 153

EZN-3889 154

EZN-3892 155

EZN-3920 156

GAL-F2 158

IMA-930 159

IMA-942 160

IMA-962 161

INO-1800 162

ITMN-10534 164

ITMN-14440 165

ITMN-30162 166

Monoclonal Antibodies to Target DR5 and FAP for Cancer 167

Monoclonal Antibody Conjugates for Solid Tumor 168

Monoclonal Antibody to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections 169

Monoclonal Antibody to Target CD16A for Oncology 170

ranibizumab SR 171

RN-486 172

RO-2959 173

RO-4938581 174

RO-5073012 175

RO-5203280 176

RO-5461111 177

Ro-646198 178

RO-6839328 179

RO-9021 180

Small Molecule to Agonize GPR119 for Type II Diabetes 181

Small Molecules for Myotonic Dystrophy Type 1 182

Small Molecules to Inhibit Janus Kinase 3 for Inflammation 184

Small Molecules to Inhibit PTP1B for Obesity and Type-2 Diabetes 185

Small Molecules to Inhibit Viral RNA Polymerase for Influenza 186

XGFR-2 187

XGFR-4 188

Fluoropyridone-19 189

Monoclonal Antibodies for Cancer 190

Proteins for Cancer 191

RG-7109 192

RO-5454948 193

RO-8994 194

Small Molecule to Activate Glycogen Synthase for Type 2 Diabetes 195

Small Molecule to Inhibit LOXL2 for Fibrosis 196

Small Molecules for Multi-Drug Resistant Gram-Negative Bacterial Infections 197

Small Molecules for Neuropsychiatric Disorders 198

Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis 199

F. Hoffmann-La Roche Ltd.-Pipeline Analysis 200

F. Hoffmann-La Roche Ltd.-Pipeline Products by Target 200

F. Hoffmann-La Roche Ltd.-Pipeline Products by Route of Administration 206

F. Hoffmann-La Roche Ltd.-Pipeline Products by Molecule Type 207

F. Hoffmann-La Roche Ltd.-Pipeline Products by Mechanism of Action 208

F. Hoffmann-La Roche Ltd.-Recent Pipeline Updates 214

F. Hoffmann-La Roche Ltd.-Dormant Projects 266

F. Hoffmann-La Roche Ltd.-Discontinued Pipeline Products 271

Discontinued Pipeline Product Profiles 273

F. Hoffmann-La Roche Ltd.-Company Statement 286

F. Hoffmann-La Roche Ltd.-Locations And Subsidiaries 288

Head Office 288

Other Locations & Subsidiaries 288

Appendix 299

Methodology 299

Coverage 299

Secondary Research 299

Primary Research 299

Expert Panel Validation 299

Contact Us 299

Disclaimer 300

List of Tables

F. Hoffmann-La Roche Ltd., Key Information 17

F. Hoffmann-La Roche Ltd., Key Facts 17

F. Hoffmann-La Roche Ltd.-Pipeline by Indication, 2015 19

F. Hoffmann-La Roche Ltd.-Pipeline by Stage of Development, 2015 27

F. Hoffmann-La Roche Ltd.-Monotherapy Products in Pipeline, 2015 28

F. Hoffmann-La Roche Ltd.-Combination Treatment Modalities in Pipeline, 2015 29

F. Hoffmann-La Roche Ltd.-Partnered Products in Pipeline, 2015 30

F. Hoffmann-La Roche Ltd.-Partnered Products/ Combination Treatment Modalities, 2015 31

F. Hoffmann-La Roche Ltd.-Out-Licensed Products in Pipeline, 2015 33

F. Hoffmann-La Roche Ltd.-Out-Licensed Products/ Combination Treatment Modalities, 2015 34

F. Hoffmann-La Roche Ltd.-Pre-Registration, 2015 35

F. Hoffmann-La Roche Ltd.-Filing rejected/Withdrawn, 2015 36

F. Hoffmann-La Roche Ltd.-Phase III, 2015 37

F. Hoffmann-La Roche Ltd.-Phase II, 2015 38

F. Hoffmann-La Roche Ltd.-Phase I, 2015 40

F. Hoffmann-La Roche Ltd.-IND/CTA Filed, 2015 42

F. Hoffmann-La Roche Ltd.-Preclinical, 2015 43

F. Hoffmann-La Roche Ltd.-Discovery, 2015 45

F. Hoffmann-La Roche Ltd.-Pipeline by Target, 2015 211

F. Hoffmann-La Roche Ltd.-Pipeline by Route of Administration, 2015 216

F. Hoffmann-La Roche Ltd.-Pipeline by Molecule Type, 2015 217

F. Hoffmann-La Roche Ltd.-Pipeline Products by Mechanism of Action, 2015 219

F. Hoffmann-La Roche Ltd.-Recent Pipeline Updates, 2015 224

F. Hoffmann-La Roche Ltd.-Dormant Developmental Projects,2015 276

F. Hoffmann-La Roche Ltd.-Discontinued Pipeline Products, 2015 281

F. Hoffmann-La Roche Ltd., Subsidiaries 298

List of Figures

F. Hoffmann-La Roche Ltd.-Pipeline by Top 10 Indication, 2015 19

F. Hoffmann-La Roche Ltd.-Pipeline by Stage of Development, 2015 27

F. Hoffmann-La Roche Ltd.-Monotherapy Products in Pipeline, 2015 28

F. Hoffmann-La Roche Ltd.-Partnered Products in Pipeline, 2015 30

F. Hoffmann-La Roche Ltd.-Out-Licensed Products in Pipeline, 2015 33

F. Hoffmann-La Roche Ltd.-Pipeline by Top 10 Target, 2015 210

F. Hoffmann-La Roche Ltd.-Pipeline by Top 10 Route of Administration, 2015 216

F. Hoffmann-La Roche Ltd.-Pipeline by Top 10 Molecule Type, 2015 217

F. Hoffmann-La Roche Ltd.-Pipeline Products by Top 10 Mechanism of Action, 2015 218

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of F. Hoffmann-La Roche Ltd.; F. Hoffmann-La Roche Ltd. - Key Therapeutics; F. Hoffmann-La Roche Ltd. - Pipeline Overview and Promising Molecules; F. Hoffmann-La Roche Ltd. - News; F. Hoffmann-La Roche Ltd. - Latest Updates; F. Hoffmann-La Roche Ltd. - Pipeline; F. Hoffmann-La Roche Ltd. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com